RU2018101897A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018101897A3 RU2018101897A3 RU2018101897A RU2018101897A RU2018101897A3 RU 2018101897 A3 RU2018101897 A3 RU 2018101897A3 RU 2018101897 A RU2018101897 A RU 2018101897A RU 2018101897 A RU2018101897 A RU 2018101897A RU 2018101897 A3 RU2018101897 A3 RU 2018101897A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015-125175 | 2015-06-22 | ||
| JP2015125175 | 2015-06-22 | ||
| PCT/JP2016/068424 WO2016208592A1 (ja) | 2015-06-22 | 2016-06-21 | 二環性複素環アミド誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018101897A RU2018101897A (ru) | 2019-07-24 |
| RU2018101897A3 true RU2018101897A3 (ru) | 2019-12-18 |
Family
ID=57584950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018101897A RU2018101897A (ru) | 2015-06-22 | 2016-06-21 | Бициклическое гетероциклическое амидное производное |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10294237B2 (ru) |
| EP (1) | EP3323809A4 (ru) |
| JP (1) | JPWO2016208592A1 (ru) |
| KR (1) | KR20180030545A (ru) |
| CN (1) | CN107922348A (ru) |
| AU (1) | AU2016284399A1 (ru) |
| CA (1) | CA2990564A1 (ru) |
| HK (1) | HK1251224A1 (ru) |
| PH (1) | PH12017502408A1 (ru) |
| RU (1) | RU2018101897A (ru) |
| SG (1) | SG11201710694YA (ru) |
| WO (1) | WO2016208592A1 (ru) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10898469B2 (en) | 2016-02-26 | 2021-01-26 | Sumitomo Dainippon Pharma Co., Ltd. | Imidazolylamide derivative |
| WO2018117127A1 (ja) * | 2016-12-20 | 2018-06-28 | 大日本住友製薬株式会社 | 未分化ｉＰＳ細胞の除去剤 |
| WO2018117196A1 (ja) * | 2016-12-20 | 2018-06-28 | 大日本住友製薬株式会社 | がん幹細胞を標的とする医薬 |
| JP6775483B2 (ja) * | 2016-12-20 | 2020-10-28 | 大日本住友製薬株式会社 | １，４−ジ置換イミダゾール誘導体からなる医薬 |
| PL3770162T3 (pl) | 2018-03-20 | 2023-06-05 | Sumitomo Pharma Co., Ltd. | Pochodne dihydrochromenu |
| US10590087B1 (en) * | 2019-08-09 | 2020-03-17 | Pfizer Inc. | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
| CN110950865B (zh) * | 2019-12-16 | 2022-05-17 | 诚达药业股份有限公司 | 一种医药中间体8-氯-1,7-萘啶-3-甲醛合成方法 |
| CN110885329B (zh) * | 2019-12-16 | 2020-12-15 | 诚达药业股份有限公司 | 一种1,7-萘啶衍生物的合成方法 |
| CN110964011B (zh) * | 2019-12-16 | 2022-06-21 | 诚达药业股份有限公司 | 一种8-氯-1,7-萘啶-3-甲醛的合成方法 |
| TW202202495A (zh) * | 2020-03-26 | 2022-01-16 | 匈牙利商羅特格登公司 | 作為ｇａｍｍａ－胺基丁酸Ａ受體次單元ａｌｐｈａ ５受體調節劑之㖠啶及吡啶并〔３，４－ｃ〕嗒𠯤衍生物 |
| CN113680386B (zh) * | 2021-08-23 | 2023-08-11 | 深圳湾实验室坪山生物医药研发转化中心 | 氮杂环卡宾-方酰胺双功能催化剂及其制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW209213B (ru) * | 1991-08-21 | 1993-07-11 | Yamanouchi Pharma Co Ltd | |
| WO1997015567A1 (de) | 1995-10-20 | 1997-05-01 | Dr. Karl Thomae Gmbh | 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung |
| US5840721A (en) | 1997-07-09 | 1998-11-24 | Ontogen Corporation | Imidazole derivatives as MDR modulators |
| PL1730119T3 (pl) | 2004-03-23 | 2008-10-31 | Pfizer Products Incorporated | Związki imidazolowe do leczenia zaburzeń neurodegeneracyjnych |
| SE0401653D0 (sv) * | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | New compounds |
| AR052666A1 (es) * | 2005-02-16 | 2007-03-28 | Solvay Pharm Bv | Derivados de 1h-imidazol como moduladores del receptor cannabinoide cb2 |
| WO2006087355A1 (en) * | 2005-02-16 | 2006-08-24 | Solvay Pharmaceuticals B.V. | 1h-imidiazole derivatives as cannabinoid cb2 receptor modulators |
| GB0508472D0 (en) | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
| WO2007034326A2 (en) * | 2005-09-22 | 2007-03-29 | Pfizer Products Inc. | Imidazole compounds for the treatment of neurological disorders |
| WO2007073299A1 (en) * | 2005-12-23 | 2007-06-28 | Astrazeneca Ab | Imidazoles as gaba-b receptor modulators |
| CA2653506A1 (en) | 2006-05-31 | 2007-12-06 | Galapagos Nv. | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases |
| WO2008073461A2 (en) | 2006-12-11 | 2008-06-19 | Wyeth | Ion channel modulators |
| JP2010513519A (ja) * | 2006-12-22 | 2010-04-30 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | キナーゼインヒビター活性を有するある種のピラゾリン誘導体 |
| US8133895B2 (en) | 2007-05-10 | 2012-03-13 | Janssen Pharmaceutica N.V. | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2008138842A1 (en) | 2007-05-10 | 2008-11-20 | Galapagos N.V. | Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases |
| US8076491B2 (en) | 2007-08-21 | 2011-12-13 | Senomyx, Inc. | Compounds that inhibit (block) bitter taste in composition and use thereof |
| GB0722075D0 (en) | 2007-11-09 | 2007-12-19 | Smithkline Beecham Corp | Compounds |
| KR101872239B1 (ko) | 2011-03-22 | 2018-06-28 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | N-(1,3,4-옥사디아졸-2-일)아릴카복사미드 및 제초제로서의 그의 용도 |
| TWI637951B (zh) | 2013-02-15 | 2018-10-11 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 |
| SI3305778T1 (sl) * | 2013-05-23 | 2022-04-29 | Kalvista Pharmaceuticals Limited | Zaviralci plazemskega kalikreina |
| JPWO2015151490A1 (ja) * | 2014-03-31 | 2017-04-13 | ボストン バイオメディカル， インコーポレイテッド | 新規な三環性キノン誘導体 |
| RU2741000C2 (ru) | 2015-06-22 | 2021-01-22 | Сумитомо Дайниппон Фарма Ко., Лтд. | Производное 1,4-дизамещенного имидазола |
| US20160376263A1 (en) | 2016-07-26 | 2016-12-29 | Senomyx, Inc. | Bitter taste modifiers including substituted 1-benzyl-3-(1-(isoxazol-4-ylmethyl)-1h-pyrazol-4-yl)imidazolidine-2,4-diones and compositions thereof |
-
2016
- 2016-06-21 EP EP16814362.6A patent/EP3323809A4/en not_active Withdrawn
- 2016-06-21 JP JP2017524928A patent/JPWO2016208592A1/ja not_active Withdrawn
- 2016-06-21 SG SG11201710694YA patent/SG11201710694YA/en unknown
- 2016-06-21 WO PCT/JP2016/068424 patent/WO2016208592A1/ja active Application Filing
- 2016-06-21 CA CA2990564A patent/CA2990564A1/en not_active Abandoned
- 2016-06-21 CN CN201680048109.XA patent/CN107922348A/zh active Pending
- 2016-06-21 AU AU2016284399A patent/AU2016284399A1/en not_active Abandoned
- 2016-06-21 RU RU2018101897A patent/RU2018101897A/ru not_active Application Discontinuation
- 2016-06-21 KR KR1020187001850A patent/KR20180030545A/ko unknown
- 2016-06-21 US US15/738,734 patent/US10294237B2/en not_active Expired - Fee Related
-
2017
- 2017-12-22 PH PH12017502408A patent/PH12017502408A1/en unknown
-
2018
- 2018-08-17 HK HK18110571.6A patent/HK1251224A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10294237B2 (en) | 2019-05-21 |
| RU2018101897A (ru) | 2019-07-24 |
| EP3323809A1 (en) | 2018-05-23 |
| JPWO2016208592A1 (ja) | 2018-04-05 |
| CA2990564A1 (en) | 2016-12-29 |
| WO2016208592A1 (ja) | 2016-12-29 |
| HK1251224A1 (zh) | 2019-01-25 |
| KR20180030545A (ko) | 2018-03-23 |
| CN107922348A (zh) | 2018-04-17 |
| AU2016284399A1 (en) | 2018-02-01 |
| PH12017502408A1 (en) | 2018-06-25 |
| EP3323809A4 (en) | 2019-01-02 |
| SG11201710694YA (en) | 2018-01-30 |
| US20180194773A1 (en) | 2018-07-12 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200421 |